HC Wainwright Forecasts Stronger Earnings for Pyxis Oncology

Pyxis Oncology, Inc. (NASDAQ:PYXS) – Stock analysts at HC Wainwright increased their Q1 2025 earnings per share estimates for Pyxis Oncology in a research note issued to investors on Wednesday, March 19th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($0.29) for the quarter, up from their previous forecast of ($0.38). HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.04) per share. HC Wainwright also issued estimates for Pyxis Oncology’s Q2 2025 earnings at ($0.31) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($1.34) EPS, FY2026 earnings at ($1.25) EPS, FY2027 earnings at ($1.17) EPS, FY2028 earnings at ($0.53) EPS and FY2029 earnings at $0.24 EPS.

A number of other research analysts have also recently weighed in on PYXS. Royal Bank of Canada reiterated an “outperform” rating and issued a $8.00 target price on shares of Pyxis Oncology in a report on Wednesday. William Blair cut Pyxis Oncology from an “outperform” rating to a “market perform” rating in a report on Thursday, November 21st. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $9.20.

Pyxis Oncology Trading Up 4.7 %

Shares of Pyxis Oncology stock opened at $1.12 on Friday. Pyxis Oncology has a twelve month low of $0.99 and a twelve month high of $6.18. The stock has a market capitalization of $66.60 million, a P/E ratio of -1.09 and a beta of 1.11. The business’s fifty day moving average price is $1.33 and its 200 day moving average price is $2.38.

Pyxis Oncology (NASDAQ:PYXS) last posted its quarterly earnings data on Tuesday, March 18th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.01.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in PYXS. LMR Partners LLP purchased a new position in Pyxis Oncology in the third quarter valued at about $294,000. Intech Investment Management LLC purchased a new position in Pyxis Oncology in the third quarter valued at about $55,000. MetLife Investment Management LLC raised its position in Pyxis Oncology by 41.1% in the third quarter. MetLife Investment Management LLC now owns 18,818 shares of the company’s stock valued at $69,000 after purchasing an additional 5,484 shares during the period. Jacobs Levy Equity Management Inc. purchased a new position in Pyxis Oncology in the third quarter valued at about $1,405,000. Finally, State Street Corp increased its position in shares of Pyxis Oncology by 28.0% during the third quarter. State Street Corp now owns 951,251 shares of the company’s stock worth $3,491,000 after acquiring an additional 208,344 shares during the last quarter. 39.09% of the stock is owned by hedge funds and other institutional investors.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.